| |
Do you find IMCL price action a bit poor lately?
Yes, I would also like to see this stock moving up more rapidly, however, from a technical standpoint it is probably better that it builds a base here at $9 to $10.
Considering its prospects, I am wondering why it hasn't tested recent highs of $14 area. I am becoming suspicious, esp. after recent presentation at H&Q.
Last year was a poor one for small biotechs. All the $ is chasing high tech at the moment; when they start to take their profits the $ will, IMHO, flow back into the biotech sector which is currently undervalued. Coverage by some more analysts is key and management is working on this. To allay your suspicion, you should call IMCL IR, Andrea F. Rabney
Director, Corporate Development & Investor Relations
ImClone Systems Incorporated
180 Varick Street
New York, NY 10014
Phone: (212) 645-1405
She is very efficient and responsive, and having spoken with her recently, i believe that she will tell you that the company is on track. |
|
